, Le protocole que nous proposons correspond à un essai clinique phase II randomisé, multicentrique, en double aveugle, NAC versus placebo

, Malgré ces limites, cette étude devrait fournir des informations sur l'efficacité de la NAC dans la diminution de la consommation d'alcool et l'amelioration de la qualité de vie chez les patients souffrant d

V. Nguyen-thanh and R. Guignard, Consommation d'alcool, comportements et conséquences pour la santé en France, Bulletin Epidemiologique Hebdomadaire Santé publique France, pp.5-6, 2019.

N. Ramoz and P. Gorwood, Genetic factors in alcohol dependence, Presse Med, vol.47, pp.547-553, 2018.

X. Laqueille, M. Lacombe, and A. Dervaux, Aspects épidémiologiques de l'alcoolodépendence, Presse Med, vol.47, p.6, 2018.

Z. Raye, L. Phd, B. B. Wilford, D. E. Falk-phd, M. L. Ryan et al., Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety, Substance Abuse, vol.37, issue.2, pp.286-298, 2016.

M. F. Olive, R. M. Cleva, P. W. Kalivas, and R. J. Malcolm, Glutamatergic medications for the treatment of drug and behavioral addictions, Pharmacol Biochem Behav, vol.100, pp.801-810, 2012.

. Gc and . Quintero, Role of nucleus accumbens glutamatergic plasticity in drug addiction

, Neuropsychiatr Dis Treat, vol.9, pp.1499-1512, 2013.

M. E. Quintanilla, M. Rivera-meza, P. Berrios-carcamo, C. Salinas-luypaert, and M. Herrera-marschitz,

Y. Israel, Beyond the "First Hit": Marked Inhibition by N-Acetyl Cysteine of Chronic Ethanol Intake But Not of Early Ethanol Intake, Parallel Effects on Ethanol-Induced Saccharin Motivation. Alcohol Clin Exp Res, vol.40, issue.5, pp.1044-51, 2016.

S. Lebourgeois, M. Gonzalez-marin, J. Jeanblanc, M. Nassila, and C. Vilpoux, Effect of N-acetylcysteine on motivation, seeking and relapse to ethanol self-administration, Addiction Biology, 2017.

J. G. Gerber, J. S. Macdonald, R. D. Harbison, J. P. Villeneuve, A. J. Wood et al., Effect of Nacetylcysteine on hepatic covalent binding of paracetamol (acetaminophen), Lancet, vol.1, pp.657-658, 1977.

, Baromètre santé 2017. Questionnaire, p.53, 2017.

, International guide for monitoring alcohol consumption and related harm, 2000.

U. K. London, Guideline on the development of medicinal products for the treatment of alcohol dependence, European Medicines Agency, 2010.

W. Van-denbrink, G. A. Aubin, H. J. Benyamina, A. Caputo, F. Dematteis et al.,

, Efficacity and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level, Addiction Biology, vol.23, pp.969-986, 2018.

C. Bonaldi and C. Hill, La mortalité attribuable à l'alcool en France en 2015, Bull Epidémiol Hebd, pp.97-108, 2019.

M. Kozak, M. Piegza, P. Scislo, and K. Badura-brzoza, Socio-demographic indicators of alcohol dependence in patients treated for addiction in a post-industrial city 2019, Int J Psychiatry Med, vol.42, issue.3, pp.227-266, 2011.

H. Klingemann and G. Gmel, Mapping the social consequences of alcohol consumption, 2001.

J. Rehm, W. Zatonksi, B. Taylor, and P. Anderson, Epidemiology and alcohol policy in Europe, Addiction, vol.106, issue.Suppl1, pp.11-19, 2011.

M. Roerecke, A. Gual, and J. Rehm, Reduction of alcohol consuption and subsequent mortality in alcohol use disorders: systematic review and meta-analyses, J Clin Psychiatry, vol.74, issue.12, 2013.

S. J. Adamson, N. Heather, V. Morton, and D. Raistrick, Initial preference for drinking goal in the treatment of alcohol problems: II.Treatment outcomes, Alcohol Alcohol, vol.45, pp.136-142, 2010.

. Has--haut-autorité-de-santé, Recommendation relative à la prise en charge à titre derogatoire de Lioresal et de Baclofène Zentiva (Baclofène) dans le cadre d'une recommendation temporaire d'utilisation

C. Palpacuer, R. Duprez, A. Huneau, C. Locher, R. Boussageon et al., Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: A systematic review with direct and network metaanalysis on nalmefene, naltrexone, acamprosate, baclofen and topiramate, Addiction, pp.1-18, 2017.

H. R. Kranzler, R. Feinn, P. Morris, and E. E. Hartwell, A Meta-analysis of the Efficacy of Gabapentin for Treating Alcohol Use Disorder, Addiction, 2019.

M. Akbar, M. Egli, Y. E. Cho, B. J. Song, and A. Noronha, Medications for alcohol use disorders : An overview, Pharmacology and Therapeutics, vol.185, pp.64-85, 2018.

F. Ng, M. Berk, O. Dean, and A. I. Bush, Oxidative stress in psychiatric disorders: evidence base and therapeutic implications, Int J Neuropsychopharmacol, vol.11, pp.851-876, 2008.

, Silva Rodrigues F Involvement of the cholinergic parameters and glial cells in learning delay induced by glutaric acid: protection by N-Acetylcysteine Mol Neurobiol, 2019.

K. S. Kau, A. Madayag, J. R. Mantsch, M. D. Grier, O. Abdulhameed et al., Blunted cystine-glutamate antiporter function in the nucleus accumbens promotes cocaine-induced drug seeking, Neuroscience, vol.155, pp.530-537, 2008.

J. Lewerenz, S. J. Hewett, Y. Huang, M. Lambros, P. W. Gout et al., The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities, Antioxid Redox Signal, vol.18, pp.522-555, 2013.

D. A. Baker, Z. X. Xi, H. Shen, C. J. Swanson, and P. W. Kalivas, The origin and neuronal function of in vivo nonsynaptic glutamate, J Neurosci, vol.22, pp.9134-9141, 2002.

M. M. Moran, K. Mcfarland, R. I. Melendez, P. W. Kalivas, and J. K. Seamans, Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking, Ibid, vol.25, pp.6389-6393, 2005.

Z. X. Xi, D. A. Baker, H. Shen, D. S. Carson, and P. W. Kalivas, Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens, J Pharmacol Exp Ther, vol.300, pp.162-171, 2002.

P. W. Kalivas, The glutamate homeostasis hypothesis of addiction, Nat Rev Neurosci, vol.10, pp.561-572, 2009.

M. D. Scofield and P. W. Kalivas, Astrocytic Dysfunction and Addiction: Consequences of Impaired Glutamate Homeostasis, Neuroscientist, 2014.

M. F. Olive, R. M. Cleva, P. W. Kalivas, and R. J. Malcolm, Glutamatergic medications for the treatment of drug and behavioral addictions, Pharmacol Biochem Behav, vol.100, pp.801-810, 2012.

G. C. Quintero, Role of nucleus accumbens glutamatergic plasticity in drug addiction

, Neuropsychiatr Dis Treat, vol.9, pp.1499-1512, 2013.

R. M. Brown, Y. M. Kupchik, and P. W. Kalivas, The story of glutamate in drug addiction and of Nacetylcysteine as a potential pharmacotherapy, JAMA Psychiatry, vol.70, pp.895-897, 2013.

A. Dahchour, D. Witte, and P. , Excitatory and inhibitory amino acid changes during repeated episodes of ethanol withdrawal: an in vivo microdialysis study, Eur J Pharmacol, vol.459, pp.171-178, 2003.

R. I. Melendez, M. P. Hicks, S. S. Cagle, and P. W. Kalivas, Ethanol exposure decreases glutamate uptake in the nucleus accumbens, Alcohol Clin Exp Res, vol.29, pp.326-333, 2005.

C. Yang, F. J. Bosker, J. Li, and R. A. Schoevers, N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial, BMC Psychiatry, vol.18, p.279, 2018.

R. J. Garcia, L. Francis, M. Dawood, Z. W. Lai, S. V. Faraone et al., Attention deficit and hyperacttivity disorder scores are elevated and respond to N-Acetylcysteine treatment in patients with systemic lupus erythematosus, Arthritis Rheum, vol.65, issue.5, pp.1313-1318, 2013.

J. R. Strawn and S. N. Saldana, Treatment with adjunctive N-Acetylcysteine in an adolescent with selective serotonin reuptake inhibitor -resistant anxiety, J. Child Adolesc, vol.22, issue.6, pp.472-473, 2012.

H. Afshar, H. Roohafza, H. Mohammad-beigi, M. Jahangard, L. Shokouh et al., N-Acetylcysteine add-on treatment in refractory obsessive-conpulsive disorder : a randomized, double -blind, placebo -control trial, J. Clin. Psychopharmacol, vol.32, issue.6, pp.797-803, 2012.

M. Nikoo, H. Radnia, M. Farokhnia, M. R. Mohammadi, and S. Akhondzadeh, N-Acetylcysteine as an adjunctive thérapy to risperidone for treatment of irritability in autism : a randomized, double -blind, placebo-controlled clinical trial of efficacy and safety, Clin. Neuropharmacol, vol.38, issue.51, pp.11-17, 2015.

R. A. Chambers, A Neurobiological Basis for Substance Abuse Comorbidity in Schizophrenia, Society of Biological Psychiatry, 2001.

M. Berk, D. Copolov, and O. Dean, N-acetyl cysteine as a glutathione precursor for schizophrenia: a double-blind, randomized, placebocontrolled trial, Biol Psychiatry, vol.64, pp.361-368, 2008.

M. Berk, D. L. Copolov, and O. Dean, N-acetyl cysteine for depressive symptoms in bipolar disorder: a double-blind randomized placebo controlled trial, Biol Psychiatry, vol.64, pp.468-475, 2008.

T. E. Robinson and K. C. Berridge, Addiction. Annu Rev Psychol, vol.54, pp.25-53, 2003.

M. D. Skinner and H. J. Aubin, Craving's place in addiction theory: contributions of the major models, Neurosci Biobehav Rev, vol.34, pp.606-623, 2010.

S. L. Amen, L. B. Piacentine, M. E. Ahmad, S. J. Li, J. R. Mantsch et al., Baker DA Repeated Nacetyl cysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans, Neuropsychopharmacology, vol.36, pp.871-878, 2011.

Y. M. Kupchik, K. Moussawi, X. C. Tang, X. Wang, B. C. Kalivas et al., The effect of Nacetylcysteine in the nucleus accumbens on neurotransmission and relapse to cocaine, Biol Psychiatry, vol.71, pp.978-986, 2012.

A. M. Ramirez-nino, D. Souza, M. S. Markou, and A. , N-acetylcysteine decreased nicotine selfadministration and cue-induced reinstatement of nicotine seeking in rats: comparison with the effects of N-acetylcysteine on food responding and food seeking, Psychopharmacology (Berl), vol.225, pp.473-482, 2013.

P. N. Mardikian, S. D. Larowe, S. Hedden, P. W. Kalivas, and R. J. Malcolm, An open-label trial of Nacetylcysteine for the treatment of cocaine dependence: a pilot study, Prog Neuropsychopharmacol Biol Psychiatry, vol.31, pp.389-94, 2007.

L. Schmaal, D. J. Veltman, A. Nederveen, W. Van-den-brink, and A. E. Goudriaan, N-acetylcysteine normalizes glutamate levels in cocaine dependent patients: a randomized crossover magnetic resonance spectroscopy study, Neuropsychopharmacology, vol.37, pp.2143-52, 2012.

E. A. Mcclure, S. C. Sonne, T. Winhusen, K. M. Carroll, U. E. Ghitza et al., Achieving Cannabis Cessation -Evaluating N-acetylcysteine Treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network, Contemp Clin Trials, vol.39, issue.2, p.211, 2014.

A. T. Roten, N. L. Baker, and K. M. Gray, Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial, Addict Behav, vol.38, pp.1788-1791, 2013.

K. M. Gray, M. J. Carpenter, N. L. Baker, S. M. Desantis, E. Kryway et al., A double -blind randomized controlled trial of N-Acetylcysteine in cannabis -dependent adolescents, Am. J Psychiatry, vol.169, issue.8, pp.805-812, 2012.

K. M. Gray, S. C. Sonne, E. A. Mcclure, . Ghitzaue, A. G. Matthews et al., A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults, Drug and alcohol dependence, vol.177, pp.249-257, 2017.

J. E. Grant, A double -blind, placebo -controlled study of N-Acetylcysteine plus naltrexone for methamphetamine dependence, Eur. Neuropsychopharmacol, vol.20, pp.823-828, 2010.

S. G. Mousavi, M. R. Sharbafchi, M. Salehi, M. Peykanpour, K. Sichani et al., The efficacity of N-Acetylcysteine in the treatment of methamphetamine dependence : a double -blind controlled, crossover study, Arch. Iran. Med, vol.18, issue.1, pp.28-33, 2015.

L. Schmaal, L. Berk, K. P. Hulstijn, J. Cousijn, and W. Rw, van den Brink W. Efficacity of N-Acetylcysteine in the treatment of nicotine dependence : a double -blind placebo -controlled pilot study, Eur Addict Res, vol.17, pp.211-217, 2011.

B. Froeliger, P. A. Mcconnell, and N. Stankeviciute, The effects of N-Acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptomsand smokingabstinence:Adoubleblind,placebocontrolled fMRI pilot study, Drug Alcohol Depend, vol.156, pp.234-242, 2015.

L. A. Knackstedt, S. Larowe, P. Mardikian, R. Malcolm, and H. Upadhyaya, The role of cystineglutamate exchange in nicotine dependence in rats and humans, Biol Psychiatry, vol.65, pp.841-845, 2009.

J. E. Grant, S. W. Kim, and B. L. Odlaug, N-acetyl cysteine, a glutamatemodulating agent, in the treatment of pathological gambling: a pilot study, Biol Psychiatry, vol.62, pp.652-659, 2007.

S. D. Larowe, P. W. Kalivas, J. S. Nicholas, P. K. Randall, P. N. Mardikian et al., Is cocaine desire reduced by N-acetylcysteine?, Am J Psychiatry, vol.164, pp.1115-1117, 2007.

S. D. Larowe, . Kalivas, J. S. Nicholas, P. K. Randall, . Pn-markidikian et al., A Double-Blind Placebo-Controlled Trial of N-Acetylcysteine in the Treatment of Cocaine Dependence, The American Journal on Addictions, vol.22, pp.443-452, 2013.

M. S. Duailibi, Q. Cordeiro, E. Brietzke, M. Riveiro, S. Larowe et al., N-Acetylcysteine in the treatement of craving in substance use disorders: Systematic review and meta-analysis, Am J Addicct, vol.26, issue.7, pp.660-666, 2017.

S. E. Back, J. L. Mccauley, K. J. Korte, D. F. Gros, V. Leavitt et al.,

, A double -blind, rondomized, controlled pilot trial of N-Acetylcysteine in veterans with posttraumatic stress disorder and substance, J Clin Psychiatry, 2016.

L. M. Squeglia, R. L. Tomko, N. L. Baker, E. A. Mcclure, G. A. Book et al., The Effect of N-Acetylcysteine on Alcohol Use during a Cannabis Cessation Trial, Drug Alcohol Depend, vol.185, pp.17-22, 2018.

G. Yoon, Acetylcysteine in alcool dependence, Clin trial, 2013.

P. Haber, The efficacy and neurobehavioural mechanism of N-Acetylcysteine for alcohol dependence, Clin trial, 2019.

N. Gray-km, Acetylcysteine for adolescent alcohol use disorder, Clin trial 2018 Identifier NCT03707951

, =1 Accédé le, vol.25, 2019.

, Clinical trial for alcohol use disorder and post traumatic stress disorder, Identifier NCT02966873, 2016.

D. Rosa, S. C. Zaretsky, M. D. Dubs, J. G. Roederer, M. Anderson et al., N-acetylcysteine replenishes glutathione in HIV infection, Eur J Clin Invest, vol.30, pp.915-92, 2000.

. Deepmala, J. Slattery, N. Kumar, L. Delhey, M. Berk et al., Clinical trials of N-Acetylcysteine in psychiatry and neurology : a systematic review, Neuroscience and Biobehavioral Reviews, vol.55, pp.294-321, 2015.

M. Ansseau, J. Besson, M. Lejoyeux, E. Pinto, U. Landry et al., A French Translation of the Obsessive-Compulsive Drinking Scale for Craving in Alcohol-Dependent Patients: A Validation Study, Eur Addict Res, vol.6, pp.51-56, 2000.

A. Gual, H. Yuan, L. Torup, W. Van-denbrink, and K. Mann, A randomised, double-blind, placebocontrolled, efficacy study of nalmefene, as-needed use

, European Neuropsychopharmacology, vol.23, issue.11, pp.1432-1442, 2013.

L. C. Sobell and M. B. Sobell, Timeline Follow-back: a technique for assessing self-reported ethanol consumption, Measuring Alcohol Consumption: Psychosocial and Biological Methods, pp.41-72, 1992.

Y. Lecrubier, D. Sheehan, E. Weiller, P. Amorim, I. Bonora et al., The MINI International Neuropsychiatric Interview (M.I.N.I.) A Short Diagnostic Structured Interview: Reliability and Validity According to the CIDI, European Psychiatry, vol.12, pp.224-231, 1997.

T. F. Babor, J. C. Higgins-biddle, J. B. Saunders, and M. G. Monteiro, The Alcohol Use Disorders Identification Test, Guidelines for Use in Primary Care. 2nd Edition Geneva. Department of Mental Health and Substance Dependence, WHO, 2001.

M. Ansseau, J. Besson, M. Lejoyeux, E. Pinto, U. Landry et al., A French translation of the obsessive-compulsive drinking scale for craving in alcohol-dependent patients: a validation study, Eur Addict Res, vol.6, issue.2, pp.51-57, 2000.

F. Charon, G. Van-woensel, and . Le, , vol.170, 2000.

K. Mann, T. Lemenager, S. Hoffmann, R. I. Hermann, D. Batra et al., Results of a double -blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study, Addict Biol, vol.18, pp.937-946, 2012.

A. N. Starosta, R. F. Leeman, and J. R. Volpicelli, The BRENDA Model: Integrating Psychosocial Treatment and Pharmacotherapy for the Treatment of Alcohol Use Disorders, J Psychiatr Pract, vol.12, issue.2, pp.80-89, 2006.

A. , N-acetylcysteine: a safe antidote for cysteine/glutathione deficiency, Curr Opin Pharmacol, vol.7, issue.4, pp.355-359, 2007.

C. Conrad, J. Lymp, V. Thompson, C. Dunn, Z. Davies et al., Long-term treatment with oral N-acetylcysteine: Affects lungfunction but not sputum inflammation in cysticfibrosis subjects.A phase II randomized placebo-controlled trial, J of Cyst Fibrosis, vol.14, issue.2, pp.219-246, 2015.

R. Z. , B. B. Wilford, M. S. , D. E. , M. L. Ryan et al., Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety, Substance Abuse, vol.37, issue.2, pp.286-298, 2016.

, American Psychiatric Association . Mini DSM -5 Critères diagnostiques. Elsevier Masson, p.347, 2018.

, Classification internationale des maladies. 10ème révision. Chapitre V (F): troubles mentaux et troubles du comportement, par l'Organisation Mondiale de la Santé, p.336, 1993.